

Form 605Corporations Act 2001
Section 671B**Notice of ceasing to be a substantial holder**

To: Company Name/Scheme

PHARMX TECHNOLOGIES LIMITED

ACN/ARSN

000 091 305**1. Details of substantial holder(1)**

Name

SEE NAMES IN ANNEXURE A

ACN/ARSN (if applicable)

SEE ANNEXURE AThe holder ceased to be a
substantial holder on21/3/2025

The previous notice was given to the company on

21/11/2019

The previous notice was dated

21/11/2019**2. Changes in relevant interests**

Particulars of each change in, or change in the nature of, a relevant interest (2) of the substantial holder or an associate (3) in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows:

Date of change	Person whose relevant interest changed	Nature of change (4)	Consideration given in relation to change(5)	Class (6) and number of securities affected	Person's votes affected
<u>NIL</u>					

3. Changes in association

The persons who have become associates (3) of, ceased to be associates of, or have changed the nature of their association (7) with, the substantial holder in relation to voting interests in the company or scheme are as follows:

Name and ACN/ARSN (if applicable)	Nature of association
<u>SEE ANNEXURE A</u>	


4. Addresses

The addresses of persons named in this form are as follows:

Name	Address
<u>SEE ANNEXURE A</u>	

Signatureprint name BEN HUGHEScapacity DIRECTOR

sign here

date 26 / 3 / 2025


For personal use only

DIRECTIONS

- (1) If there are a number of substantial holders with similar or related relevant interests (eg. a corporation and its related corporations, or the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 4 of the form.
- (2) See the definition of "relevant interest" in sections 608 and 671B(7) of the Corporations Act 2001.
- (3) See the definition of "associate" in section 9 of the Corporations Act 2001.
- (4) Include details of:
- (a) any relevant agreement or other circumstances because of which the change in relevant interest occurred. If subsection 671B(4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and
 - (b) any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification applies).
- See the definition of "relevant agreement" in section 9 of the Corporations Act 2001.
- (5) Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired.
- (6) The voting shares of a company constitute one class unless divided into separate classes.
- (7) Give details, if appropriate, of the present association and any change in that association since the last substantial holding notice.

ANNEXURE A

FORM 605
NOTICE OF CEASING TO BE A SUBSTANTIAL HOLDER
PHARMX TECHNOLOGIES LIMITED
ACN: 000 091 305
MERSAULT PTY LTD <THE ENGLAND SUPER FUND A/C> AND OTHERS

This is Annexure A of 2 pages referred to in Form 605, Notice of ceasing to be a substantial holder, lodged by Alchemy Healthcare Pty Ltd and others in respect of PharmX Technologies Limited.

1. Details of substantial holder (1)

Name	ACN/ARSN
MERSAULT PTY LTD <THE ENGLAND SUPER FUND A/C>	142 611 443
LYELL PTY LIMITED <HAYMAN A/C>	091 468 503
QUANTUMEDGE HOLDINGS PTY LTD <GENESIS SUPER FUND A/C> (formerly LYELL PTY LTD <GENESIS SUPER FUND A/C>)	680 316 072 (formerly 091 468 503)
DG MANUEL AND AE LEARY <MANUEL FAMILY A/C>	N/A
DG MANUEL AND AE LEARY <MANUEL SUPER FUND A/C>	N/A

2. Changes in relevant interests

NIL

3. Changes in association

Name and ACN/ARSN (if applicable)	Nature of association
MERSAULT PTY LTD <THE ENGLAND SUPER FUND A/C> ACN: 142 611 443	CEASED ASSOCIATION (a)
LYELL PTY LIMITED <HAYMAN A/C> ACN: 091 468 503	CEASED ASSOCIATION (a, b)
QUANTUMEDGE HOLDINGS PTY LTD <GENESIS SUPER FUND A/C> (formerly LYELL PTY LTD <GENESIS SUPER FUND A/C>) ACN: 680 316 072 (formerly 091 468 503)	CEASED ASSOCIATION (a, b)
DG MANUEL AND AE LEARY <MANUEL FAMILY A/C> ACN: N/A	CEASED ASSOCIATION (a, c)

DG MANUEL AND AE LEARY <MANUEL SUPER FUND A/C> ACN: N/A	CEASED ASSOCIATION (a, c)
--	---------------------------

- (a) Alchemy Healthcare Pty Ltd was deregistered by ASIC on 21 March 2025.
- (b) LYELL PTY LIMITED <HAYMAN A/C> and QUANTUMEDGE HOLDINGS PTY LTD <GENESIS SUPER FUND A/C> remain associates of each other but not of other entities listed above.
- (c) DG MANUEL AND AE LEARY <MANUEL FAMILY A/C> and DG MANUEL AND AE LEARY <MANUEL SUPER FUND A/C> remain associates of each other but not of other entities listed above.

4. Addresses

Name	Address
MERSAULT PTY LTD <THE ENGLAND SUPER FUND A/C>	23A STATION STREET HORNSBY NSW 2077
LYELL PTY LIMITED <HAYMAN A/C>	UNIT 7, 29 HOOD STREET SUBIACO WA 6008
QUANTUMEDGE HOLDINGS PTY LTD <GENESIS SUPER FUND A/C>	UNIT 7, 29 HOOD STREET SUBIACO WA 6008
DG MANUEL AND AE LEARY <MANUEL FAMILY A/C>	46 WELD STREET NEDLANDS WA 6009
DG MANUEL AND AE LEARY <MANUEL SUPER FUND A/C>	46 WELD STREET NEDLANDS WA 6009

SIGNED BY: BEN HUGHES

SIGNATURE:



DATE: 26 March 2025